Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

Jaroszewicz, Jerzy; Pawłowska, Małgorzata; Simon, Krzysztof; Zarębska-Michaluk, Dorota; Lorenc, Beata; Klapaczyński, Jakub; Tudrujek-Zdunek, Magdalena; Sitko, Marek; Mazur, Włodzimierz; Janczewska, Ewa; Paluch, Katarzyna; Dybowska, Dorota; Buczyńska, Iwona; Czauż-Andrzejuk, Agnieszka; Berak, Hanna; Krygier, Rafał; Piasecki, Maciej; Dobracka, Beata; Citko, Jolanta; Piekarska, Anna; Socha, Łukasz; Deroń, Zbigniew; Tronina, Olga; Laurans, Łukasz; Białkowska, Jolanta; Tomasiewicz, Krzysztof; Halota, Waldemar; Flisiak, Robert

doi:10.1080/14787210.2020.1782189

Cited by 13 publications

(11 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, one of our patients had evidence of past HBV infection with detectable anti-HBc total antibodies. He was closely monitored during and after the treatment, and reactivation of the HBV infection did not occur (ALT and AST levels were normal, HBV DNA was undetectable during and after the treatment) [ 26 ]. In a large cohort of adults with HCV/HBV coinfection treated with DAAs, the risk of HBV reactivation in HBsAg-negative/anti-HBc-positive patients was only 0.16% [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

“…He was closely monitored during and after the treatment, and reactivation of the HBV infection did not occur (ALT and AST levels were normal, HBV DNA was undetectable during and after the treatment) [ 26 ]. In a large cohort of adults with HCV/HBV coinfection treated with DAAs, the risk of HBV reactivation in HBsAg-negative/anti-HBc-positive patients was only 0.16% [ 26 ]. To avoid HBV reactivation in patients with serologic evidence of a previous or current HBV infection, the clinical and laboratory signs of a hepatitis flare or HBV reactivation should be monitored during treatment with DAAs and posttreatment follow-up.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project

Pokorska‐Śpiewak

Dobrzeniecka²,

Aniszewska

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of LDV/SOF (90/400 mg) for the treatment of chronic hepatitis C (CHC) genotypes 1 and 4 in children aged 12 to 17 years. Methods: We analyzed intention-to-treat (ITT) and per-protocol (PP) rates of sustained virological response (SVR), defined as undetectable HCV viral load at posttreatment week 12, in 37 participants treated with LDV/SOF according to the HCV genotype, baseline liver fibrosis, duration of treatment, and experience of the previous ineffective antiviral treatment. There were 32 patients infected with genotype 1 and 5 with genotype 4. Fourteen (38%) participants were treatment-experienced, two were coinfected with HIV, and three were cirrhotic. Two patients qualified for 24 weeks of therapy, and the remaining 35 received 12 weeks of LDV/SOF treatment. Results: The overall ITT SVR12 rate was 36/37 (97%). One patient was lost to follow-up after week 4 of therapy when his HCV RNA was undetectable. All 36 patients who completed the full protocol achieved SVR (36/36, 100%). PP analyses of SVR12 rates according to the HCV genotype, baseline liver fibrosis, duration of the treatment, and previous ineffective treatment were all 100%. A significant decrease in aminotransferase serum levels was observed in the subsequent weeks of the treatment and at SVR assessment compared to baseline. No serious adverse events were reported. Conclusions: The results of this study confirm previous observations of a suitable efficacy and safety profile of LDV/SOF for the treatment of CHC genotypes 1 and 4 in adolescents.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project

Pokorska‐Śpiewak

Dobrzeniecka²,

Aniszewska

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Initially reported mainly in Asia, life-threatening emergencies from HBV reactivation in HCV co-infected individuals resulted from inadequate monitoring of HBV infection. Contemporary studies suggest that despite the relatively high frequency of previous exposure to HBV and latent hepatitis B in HCV-infected patients in Poland, the risk of HBV reactivation during DAA therapy in hepatitis B surface antigen (HBsAg) positive patients is relatively low, and in HBsAg(–)/anti-hepatitis B core (HBc) positive patients HBV reactivation seems to be limited to immunodeficient individuals [ 26 ].…”

Section: General Recommendationsmentioning

confidence: 99%

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023

Tomasiewicz¹,

Flisiak²,

Jaroszewicz³

et al. 2023

ceh

Self Cite

View full text Add to dashboard Cite

The recommendations define the principles of diagnosis and treatment of hepatitis C virus (HCV) infection according to the latest knowledge. The main goal of the treatment of HCV infection is to eliminate the virus from the body, which in turn leads to stopping the progression or causes the regression of previously formed changes in the liver. The current version of the guidelines prioritizes pangenotypic regimens and includes guidelines for special patient populations such as children, patients with cirrhosis, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection, patients with renal failure, liver failure and lack of response to previous therapies as well as patients in the peri-transplant period.

show abstract

“…Recent studies have shown that the incidence of hepatitis B has greatly decreased [7,8], but approximately 120 million people in China remain as hepatitis B virus (HBV) carriers [9]. Moreover, Chongqing Municipality has 3,000,000 urban residents with a high prevalence of hepatitis B (707.97/100,000) [10,11]when compared with other countries such as Europe, Singapore, and Japan [12][13][14]. As a large country affected by hepatitis B, China will make great contribution to the goal of eliminating hepatitis B worldwide in 2030 [15].…”

Section: Introductionmentioning

confidence: 99%

Qualitative Interviews on The Diagnosis Process of Hepatitis B Among 50 Patients in Chongqing, China

Zhou

zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: To identify the obstacles preventing and controlling hepatitis B and put forward suggestions for its prevention and treatment by describing the discovery process of hepatitis B patients. Methods: We conducted face-to-face interviews with 50 hepatitis B patients in Chongqing, China from July to August 2019 by constructing a thematic analysis framework, which included interviewees’ social demographic characteristics, diagnosis approach, signs and symptoms at the time of discovery, feelings after diagnosis, and doctor’s instructions.Results: Most of the patients were firstly found hepatitis B via physical examination when patients were asymptomatic or had no obvious symptoms. The majority of them were shocked, frightened, and at a loss when they were diagnosed. The patients could remember doctor’s instructions on keeping healthy lifestyle, but they had very little impression about doctors’ reminding about regular liver function test. Failure of regular follow-up to liver function test brought irreversible loss for certain patients.Conclusions: Most of the patients were found hepatitis B passively. The patients need professional mental help after the diagnosis to overcome the negative emotion. The doctors’ instruction should emphasize more on the importance of regular follow-up to liver function test besides health lifestyle.

show abstract

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

Cited by 13 publications

References 44 publications

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023

Qualitative Interviews on The Diagnosis Process of Hepatitis B Among 50 Patients in Chongqing, China

Contact Info

Product

Resources

About